Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
' c- N( @8 H7 ^0 n, b& p# M' u/ \& y
. v: J: ^* e1 c$ R N1 f3 F
Sub-category:
' Y V' w0 j, @/ w* RMolecular Targets ! G$ ^: D7 ^' K1 s
2 r" T6 K' _6 L2 J% Z
) R% `- Q( u/ z/ M" D
Category:
- i7 A9 @0 X# c( ^( f- ]: vTumor Biology 9 s' ]9 Y0 f9 L5 O: k7 I# k0 \
@% I3 `0 K+ t, k! _
8 L( \! z: \# [1 j6 w- B0 w' O) y
Meeting:
- C. M7 K5 z7 P2 {3 e2011 ASCO Annual Meeting " S; w' R- \, A8 F
8 w3 J$ E' c9 V
, K( I* ]& f( }, I6 E. MSession Type and Session Title:5 ~$ V" k1 R) {0 R
Poster Discussion Session, Tumor Biology
* i8 \: N5 P9 A1 ?1 m1 ?9 r$ l$ ]0 g3 q
- m# k) ^& v. a! r9 O' \1 U5 DAbstract No:6 q6 W) g+ V5 L& d8 t
10517 $ ]. S( f. N- Z8 k! r" ?
" b: N: m3 M0 Y& i
- c* n4 Y$ g: h8 X
Citation: t9 P% u) z2 A& ^9 \
J Clin Oncol 29: 2011 (suppl; abstr 10517)
: m& V" D8 L. Z% e! Y$ t: w. ^+ ^5 j1 J# n. r
; P' g; s1 n- F) R
Author(s):* y- L0 v' f# y, Y
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China ( `/ w! s# j, \: Z/ c$ M# u% a
4 U$ z2 u- k. }! l4 d0 v) }
, X# u8 L% a1 |( _& ?4 U! e
+ B1 _, M* i+ k! i% ~5 nAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings./ L% X4 i8 t) N) `
$ `1 H: ]4 Y! L/ F8 A4 [! j- FAbstract Disclosures; S& T/ ]& K. t- J" z6 I4 y
1 `0 t/ g: A. v" G6 K, WAbstract:
2 p2 U& j8 e, ` o. d, ?; z, b; S0 l _- S8 d
2 X3 i8 c8 X, F% e" e
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
8 n# E f6 u% y: f+ r
4 V* f: ^( s5 Q E
! ]! ? _) y, m/ t6 P( ~. s7 J |
& p1 o6 E4 M" b& b; A0 P9 d
显身卡
